Neurocrine biosciences to present data on treatment patterns and unmet needs in adult and pediatric patients living with classic congenital adrenal hyperplasia at amcp 2022

San diego , march 28, 2022 /prnewswire/ -- neurocrine biosciences, inc. (nasdaq: nbix) today announced that it will present new data on treatment patterns and unmet needs in adult and pediatric patients with classic congenital adrenal hyperplasia (cah) at the academy of managed care pharmacy (amcp) 2022 annual meeting in chicago on march 29–april 1. the three studies being presented evaluate the treatment patterns, healthcare-related costs, medication preferences, and unmet needs of patients with classic cah.
NBIX Ratings Summary
NBIX Quant Ranking